ReviewDrug safety2005
Drug-induced hypomagnesaemia : scope and management.
Review in Drug safety, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 74 citations in OpenAlex.
- N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.European journal of clinical pharmacology · 2014Trial
- Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients.Biological trace element research · 2012Trial
- Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir.Frontiers in cell and developmental biology · 2023Article
- The impact of medication on osseointegration and implant anchorage in bone determined using removal torque-A review.Heliyon · 2022Article
- Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.Pediatric nephrology (Berlin, Germany) · 2021Article
- An overview of diagnosis and management of drug-induced hypomagnesemia.Pharmacology research & perspectives · 2021Review
- Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies.Cureus · 2021Article
- Drug-Induced Hypophosphatemia: Current Insights.Drug safety · 2020Review
- Magnesium and Human Health: Perspectives and Research Directions.International journal of endocrinology · 2018Review
- Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.Therapeutic advances in drug safety · 2017Article
- Frequency and Associated Factors of Amphotericin B Nephrotoxicity in Hospitalized Patients in Hematology-Oncology Wards in the Southwest of Iran.Nephro-urology monthly · 2016Article
- Proton pump inhibitor associated hypomagnasaemia - a cause for concern?British journal of clinical pharmacology · 2016Article
- Lower incidence of hypo-magnesemia in surgical intensive care unit patients in 2011 versus 2001.Journal of clinical medicine research · 2015Article
- Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.Journal of the Association for Research in Otolaryngology : JARO · 2014Article
- Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.European journal of clinical pharmacology · 2013Review
- Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone.Journal of bone and mineral metabolism · 2011Article
- Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study.Indian journal of pharmacology · 2010Article
- Magnesium disorders: clinical experience and review of the literature.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2009Article
- Renal magnification by EGF.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2008Review
- Endocrine sequelae of cancer and cancer treatments.Journal of cancer survivorship : research and practice · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nearly 50 medications have been implicated as inducing hypomagnesaemia, sometimes based on insufficient data regarding clinical significance and frequency of occurrence. In fact, clinical effects attributed to hypomagnaesemia have been reported in only 17 of these drugs. A considerable amount of literature relating to individual drugs has been published, yet a comprehensive overview of this issue is not available and the hypomagnesaemic effect of a drug could be either overemphasised or under-rated. In addition, there are neither guidelines regarding treatment, prevention and monitoring of drug-induced hypomagnesaemia nor agreement as to what serum level of magnesium may actually be defined as 'hypomagnesaemia'. By compiling data from published papers, electronic databases, textbooks and product information leaflets, we attempted to assess the clinical significance of hypomagnesaemia induced by each drug. A practical approach for managing drug-induced hypomagnesaemia, incorporating both published literature and personal experience of the physician, is proposed. When drugs classified as inducing 'significant' hypomagnesaemia (cisplatin, amphotericin B, ciclosporin) are administered, routine magnesium monitoring is warranted, preventive treatment should be considered and treatment of hypomagnesaemia should be initiated with or without overt clinical manifestations. In drugs belonging to the 'potentially significant' category, among which are amikacin, gentamicin, laxatives, pentamidine, tobramycin, tacrolimus and carboplatin, magnesium monitoring is justified when either of the following occurs: clinical manifestations are apparent; persistent hypokalaemia, hypocalcaemia or alkalosis are present; other precipitating factors for hypomagnesaemia coexist; or treatment is with more than one potentially hypomagnesaemic drug. No preventive treatment is required and treatment should be initiated only if hypomagnesaemia is accompanied by symptoms or clinically significant relevant laboratory findings. In those drugs whose hypomagnesaemic effect is labelled as 'questionable', including furosemide and hydrochlorothiazide, routine monitoring and treatment are not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.